Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials

INTRODUCTION: Subcutaneous (SC) injection is a common route of drug administration; however, injection site pain (ISP) might create a negative patient experience. We evaluated ISP, bioequivalence, and overall safety of the citrate-free (CF) formulation of ixekizumab, a high-affinity monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Chabra, Sanjay, Gill, B. J., Gallo, Gaia, Zhu, Danting, Pitou, Celine, Payne, Christopher D., Accioly, Ana, Puig, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022732/
https://www.ncbi.nlm.nih.gov/pubmed/35449322
http://dx.doi.org/10.1007/s12325-022-02126-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022732/
https://www.ncbi.nlm.nih.gov/pubmed/35449322
http://dx.doi.org/10.1007/s12325-022-02126-0

Ejemplares similares